(AOF) – Carmat has reached an agreement with all of its financial creditors on new terms for repaying its bank loans. This agreement follows the conditional agreements in principle announced on January 12 and February 22. It covers all of the company’s bank loans, including the loan for a principal amount of 30 million euros contracted with the European Investment Bank and the two loans guaranteed by the State of principal amount of 5 million euros each, contracted with BNP Paribas and Bpifrance.
“Its implementation allows us to extend the maturity of all our financial debts by at least two years, and thus reduce our loan repayments by more than 30 million euros over the period 2024-2025. We will be able to therefore, during this period, allocate our financial resources primarily to the service of our growth, but also significantly reduce the company’s financing needs”, explained the general director, Stéphane Piat.
Taking into account this agreement and its cash flow situation, the medtech can finance its activities, according to its current business plan, until mid-May 2024, and estimates its financing need over the next 12 months at around €35 million. euros.
Carmat continues to work very actively on other initiatives to strengthen its equity in the short term and alleviate its cash flow constraints, and thus be able to continue its activities beyond mid-May 2024.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.